{"filing":{"accession_number":"0001648257-26-000047","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"hcm-20260702x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000047/hcm-20260702x6k.htm"},"events":[{"id":15657,"run_id":13958,"accession_number":"0001648257-26-000047","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces NMPA (China's drug regulator) conditional approval of ORPATHYS® (savolitinib) for MET-amplified gastric cancer, marking the third approved indication for the drug in China. The approval is a significant regulatory and commercial milestone for HUTCHMED's proprietary drug platform, supported by pivotal Phase II trial data published in Nature Medicine. While not a discrete M\u0026A, financing, or governance event, this regulatory approval of a marketed therapeutic product represents a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's pipeline execution and commercial prospects.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13521,"accession_number":"0001648257-26-000047","item_number":"EX-99.1","item_title":"hcm-20260702xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NMPA (China's drug regulator) conditional approval of ORPATHYS® (savolitinib) for MET-amplified gastric cancer, marking the third approved indication for the drug in China. The approval is a significant regulatory and commercial milestone for HUTCHMED's proprietary drug platform, supported by pivotal Phase II trial data published in Nature Medicine. While not a discrete M\u0026A, financing, or governance event, this regulatory approval of a marketed therapeutic product represents a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's pipeline execution and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:09:38.256197+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13521,"accession_number":"0001648257-26-000047","item_number":"EX-99.1","item_title":"hcm-20260702xex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NMPA (China's drug regulator) conditional approval of ORPATHYS® (savolitinib) for MET-amplified gastric cancer, marking the third approved indication for the drug in China. The approval is a significant regulatory and commercial milestone for HUTCHMED's proprietary drug platform, supported by pivotal Phase II trial data published in Nature Medicine. While not a discrete M\u0026A, financing, or governance event, this regulatory approval of a marketed therapeutic product represents a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's pipeline execution and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:09:38.256197+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-07-02"}]}